Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elsulfavirine - Viriom

Drug Profile

Elsulfavirine - Viriom

Alternative Names: Elpida; elpivirine; R1206; RO 4970335; RO 5011500; VM 1500

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer National Institutes of Health (USA); Viriom
  • Class Acetamides; Antivirals; Nitriles; Small molecules; Sulfones
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 03 Dec 2019 Preclinical trials in HIV infections in USA (PO)
  • 02 Jul 2019 Viriom enters into a licensing agreement with Lloyds Pharma for elsulfavirine and other drugs from Viriom HIV and Hepatitis B portfolio in Indonesia
  • 03 Jun 2019 Preregistration for HIV infections in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top